Pay in 4 interest-free payments of $21.25 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
It occupies a novel allosteric binding site and is noncompetitive with both the peptide substrate and cofactor
3-dimethyl-7-oxo-4-thia-1-azabicyclo[3
Lillycrop KA
administration of all doses of Cariprazine (mean±SEM: 0
Induction of the MYC oncogene increases the ML-792-mediated viability effect in cancer cells
Lenalidomide Catalog No.:M8013-2 It occupies a novel allostericLenalidomide, also known as CC 5013, is the thalidomide analog with potential antineoplastic activity. Lenalidomide inhibits TNF alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis. This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells. Lenalidomide is an approved drug. Product information CAS
US$ 41.00
US$ 13.00
US$ 26.00
US$ 18.00
US$ 25.00
US$ 49.99
US$ 16.00
US$ 40.00